New combo therapy shows promise for Hard-to-Treat breast cancer

NCT ID NCT07498478

Recruiting now Disease control Sponsor: TransThera Sciences (Nanjing), Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding tinengotinib to fulvestrant can shrink tumors in people with a common type of advanced breast cancer (HR+/HER2-). About 94 adults whose cancer has returned or spread despite prior treatments will take part. The goal is to find the best dose and see if the combination works better than tinengotinib alone, while monitoring side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
NOT_YET_RECRUITING

Beijing, China
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, 100021, China
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING

Shanghai, China
Guangdong Provincial People's Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, China
Jiangsu Province Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, China
Linyi Cancer Hospital
RECRUITING

Linyi, Shandong, China
Shandong Cancer Hospital
NOT_YET_RECRUITING

Jinan, Shandong, China
Southwest Hospital
NOT_YET_RECRUITING

Chongqing, China
The First Medical Center, Chinese PLA General Hospital
NOT_YET_RECRUITING

Beijing, China
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITING

Tianjin, China
Zhejiang Cancer Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China
Zhongnan Hospital of Wuhan University
NOT_YET_RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.